Alexander Bukreyev, MS, PhD, director of the Center for Nucleic Acid Technologies and a professor in the Department of Pathology at The University of Texas Medical Branch (UTMB), has been named a 2026 fellow of the International Society for Vaccines in recognition of his contributions to vaccine research and development.
The honor was presented during the 2026 ISV Annual Congress, held Oct. 12-14 in Antwerp, Belgium.
The ISV Fellows program recognizes scientists for excellence in vaccine research and development, service to the broader vaccine community, and contributions to the society.
“Being elected a fellow of the International Society for Vaccines is a deeply meaningful recognition,” Bukreyev said. “Professionally, it reflects the dedication of our entire team and collaborators at UTMB and other institutions who work tirelessly to advance vaccine science and research against high-consequence pathogens.
“Personally, receiving this honor from my peers in the global scientific community is extraordinarily humbling, and it reinforces our commitment to developing lifesaving technologies and mentoring the next generation of researchers.”
Bukreyev’s research focuses on emerging viral infections, viral immunology, and the development of vaccines and other medical countermeasures against infectious diseases. His laboratory at UTMB studies high-consequence pathogens, including Ebola, Marburg, and Lassa viruses.
The International Society for Vaccines is a global nonprofit organization dedicated to advancing the development and use of vaccines to prevent and control infectious and noninfectious diseases in humans and animals.
Its annual congress brings together researchers, scientists, and industry leaders from around the world to exchange scientific advances, foster collaboration, and promote innovation in vaccine research and development.